Literature DB >> 14583304

Surgical results of patients with a functional single ventricle.

Jeong Ryul Lee1, Jae Sung Choi, Chang Hyun Kang, Eun Jung Bae, Yong Jin Kim, Joon Ryang Rho.   

Abstract

OBJECTIVE: Overall mortality of the patients with a functional single ventricle is still high, though excellent mid- and long-term results of the modified Fontan procedure have been reported. This study assessed the factors that affect the surgical outcomes mainly in the pre-Fontan stage and performed long-term survival analysis.
METHODS: Between January 1988 and December 2000, 405 patients with a functional single ventricle underwent surgical interventions and were followed up until June 2001. The mean follow-up period was 74.5+/-69.4 months and 95% of the patients were followed up completely. Their median age was 2.5 months at the time of shunt or pulmonary artery banding (PAB), 8.6 months at BCPS, and 28.6 months at the Fontan operation. The variables of the anatomical lesions with single ventricle physiology, combined abnormalities, surgical pathways leading to the Fontan stage, age at operation, study periods, and type of the Fontan procedure were analyzed. The role of BCPS in the long-term results was evaluated.
RESULTS: Overall survival after birth was 60.1+/-2.8% at 10 years. In multivariate analysis, complete atrioventricular septal defect-typed lesion, pulmonary venous obstruction, total anomalous pulmonary venous connection, and interruption of aortic arch were risk factors for long-term survival, while pulmonary stenosis was demonstrated as a favorable prognostic factor. In this study, there was no significant survival difference between the early and late study period. Actuarial mortality in the pre-Fontan stage was 41.3% in the non-BCPS group and 16.3% in the BCPS group (P<0.001). The 10-year survival rates of the populations in staged and primary Fontan groups were not significantly different (P=0.24). The long-term survival rate of the atriopulmonary Fontan group was significantly lower than that of lateral tunnel Fontan (60.3+/-6.3% vs. 86.8+/-3.1% at 10 years, P=0.0001).
CONCLUSION: This study revealed that the overall survival was disappointing and there were still problems that need to be solved in the pre-Fontan stage to improve the overall survival. The role of BCPS was not to contribute to the longer survival after Fontan operation, but to lower mortality in the pre-Fontan stage, which can offer a higher probability to proceed to the Fontan procedure successfully.

Entities:  

Mesh:

Year:  2003        PMID: 14583304     DOI: 10.1016/s1010-7940(03)00495-0

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Hemodynamic study of TCPC using in vivo and in vitro 4D Flow MRI and numerical simulation.

Authors:  Alejandro Roldán-Alzate; Sylvana García-Rodríguez; Petros V Anagnostopoulos; Shardha Srinivasan; Oliver Wieben; Christopher J François
Journal:  J Biomech       Date:  2015-03-19       Impact factor: 2.712

2.  Imaging and patient-specific simulations for the Fontan surgery: current methodologies and clinical applications.

Authors:  Diane A de Zélicourt; Alison Marsden; Mark A Fogel; Ajit P Yoganathan
Journal:  Prog Pediatr Cardiol       Date:  2010-12-01

3.  Risk Factors for Prolonged Pleural Effusion After Extracardiac Fontan Operation.

Authors:  Geena Kim; Hoon Ko; Joung-Hee Byun; Hyoung Doo Lee; Hyungtae Kim; Si Chan Sung; Kwang Ho Choi
Journal:  Pediatr Cardiol       Date:  2019-08-21       Impact factor: 1.655

4.  Dynamic Mode Decomposition of Fontan Hemodynamics in an Idealized Total Cavopulmonary Connection.

Authors:  Yann T Delorme; Anna-Elodie M Kerlo; Kameswararao Anupindi; Mark D Rodefeld; Steven H Frankel
Journal:  Fluid Dyn Res       Date:  2014-08       Impact factor: 1.067

5.  Externally applied compression therapy for Fontan patients.

Authors:  Joseph Hernandez; Steven G Chopski; Sam Lee; William B Moskowitz; Amy L Throckmorton
Journal:  Transl Pediatr       Date:  2018-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.